BlackRock, Inc. 13D and 13G filings for Taysha Gene Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA |
BlackRock Inc. BLK |
13,520,533 6.600% |
0 (Unchanged) |
Filing |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA |
BlackRock Inc. BLK |
13,520,533 6.600% |
12,474,043 (+1191.99%) |
Filing |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Taysha Gene Therapies, Inc. TSHA |
BlackRock Inc. BLK |
1,046,490 2.600% |
-1,986,473 (-65.50%) |
Filing |
| 2022-02-07 4:41 pm Purchase |
2021-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
BlackRock Inc. BLK |
3,032,963 7.900% |
803,147 (+36.02%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
BlackRock Inc. BLK |
2,229,816 5.900% |
2,229,816 (New Position) |
Filing |